Laura R Prakash1, Huamin Wang2, Jun Zhao2, Graciela M Nogueras-Gonzalez3, Jordan M Cloyd1, Ching-Wei D Tzeng1, Michael P Kim1, Jeffrey E Lee1, Matthew H G Katz4. 1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX, 77030, USA. 2. Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX, 77030, USA. mhgkatz@mdanderson.org.
Abstract
BACKGROUND: Resection of the superior mesenteric and/or portal vein (SMV-PV) is increasingly performed with pancreatectomy for adenocarcinoma. We sought to analyze the impact of cancer at the transected edge(s) of the vein wall. METHODS: Patients who underwent pancreatectomy with vein resection between 2003 and 2015 at a single center were evaluated. R1 resection was defined per guidelines from the American Joint Commission on Cancer and the College of American Pathologists. Specimens were also evaluated for the presence (V+) or absence (V-) of cancer cells at the transected edge(s) and depth of vein invasion. RESULTS: Among 127 evaluated patients, 114 (90%) received preoperative therapy. R-status was categorized as margin-negative (R0)/V- (n = 72, 57%), R0/V+ (n = 19, 15%), margin-positive (R1)/V- (n = 24, 19%), and R1/V+ (n = 12, 9%). Patients with V- specimens had similar median durations of recurrence-free survival (RFS) (12 vs 9 months) and overall survival (OS) (30 vs 28 months) as did patients with V+ specimens (P > 0.05). In contrast, cancer invasion into the lumen was associated with RFS and OS (P < 0.05). Among patients who underwent R0 resection, V-status had no association with OS, RFS, or local control (P > 0.05). CONCLUSION: Cancer invasion into the superior mesenteric and/or portal vein was adversely associated with survival, but cancer at the vein edge(s) was not. Transection of the SMV-PV through macroscopically normal vein may be performed to minimize resected vein length without fear of negatively affecting oncologic outcomes.
BACKGROUND: Resection of the superior mesenteric and/or portal vein (SMV-PV) is increasingly performed with pancreatectomy for adenocarcinoma. We sought to analyze the impact of cancer at the transected edge(s) of the vein wall. METHODS:Patients who underwent pancreatectomy with vein resection between 2003 and 2015 at a single center were evaluated. R1 resection was defined per guidelines from the American Joint Commission on Cancer and the College of American Pathologists. Specimens were also evaluated for the presence (V+) or absence (V-) of cancer cells at the transected edge(s) and depth of vein invasion. RESULTS: Among 127 evaluated patients, 114 (90%) received preoperative therapy. R-status was categorized as margin-negative (R0)/V- (n = 72, 57%), R0/V+ (n = 19, 15%), margin-positive (R1)/V- (n = 24, 19%), and R1/V+ (n = 12, 9%). Patients with V- specimens had similar median durations of recurrence-free survival (RFS) (12 vs 9 months) and overall survival (OS) (30 vs 28 months) as did patients with V+ specimens (P > 0.05). In contrast, cancer invasion into the lumen was associated with RFS and OS (P < 0.05). Among patients who underwent R0 resection, V-status had no association with OS, RFS, or local control (P > 0.05). CONCLUSION:Cancer invasion into the superior mesenteric and/or portal vein was adversely associated with survival, but cancer at the vein edge(s) was not. Transection of the SMV-PV through macroscopically normal vein may be performed to minimize resected vein length without fear of negatively affecting oncologic outcomes.
Entities:
Keywords:
Margins of excision; Pancreas cancer; Pancreatectomy; Survival; Veins
Authors: Kiril Trpkov; David J Grignon; Stephen M Bonsib; Mahul B Amin; Athanase Billis; Antonio Lopez-Beltran; Hemamali Samaratunga; Pheroze Tamboli; Brett Delahunt; Lars Egevad; Rodolfo Montironi; John R Srigley Journal: Am J Surg Pathol Date: 2013-10 Impact factor: 6.394
Authors: Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Matthew H G Katz; Jeffrey E Lee; Peter W T Pisters; Roman Skoracki; Eric Tamm; Jason B Fleming Journal: J Am Coll Surg Date: 2012-08 Impact factor: 6.113
Authors: Li Liu; Matthew H Katz; Sun M Lee; Laurice K Fischer; Laura Prakash; Nathan Parker; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Peter W Pisters; Anirban Maitra; Jason B Fleming; Jeannelyn Estrella; Asif Rashid; Huamin Wang Journal: Am J Surg Pathol Date: 2015-10 Impact factor: 6.394
Authors: Rebecca A Snyder; Laura R Prakash; Graciela M Nogueras-Gonzalez; Michael P Kim; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Jason B Fleming; Matthew H G Katz; Ching-Wei D Tzeng Journal: J Surg Oncol Date: 2018-05-03 Impact factor: 3.454
Authors: Emre F Yekebas; Dean Bogoevski; Guellue Cataldegirmen; Christina Kunze; Andreas Marx; Yogesh K Vashist; Paulus G Schurr; Lena Liebl; Sabrina Thieltges; Karim A Gawad; Claus Schneider; Jakob R Izbicki Journal: Ann Surg Date: 2008-02 Impact factor: 12.969
Authors: Chandrajit P Raut; Jennifer F Tseng; Charlotte C Sun; Huamin Wang; Robert A Wolff; Christopher H Crane; Rosa Hwang; Jean-Nicolas Vauthey; Eddie K Abdalla; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans Journal: Ann Surg Date: 2007-07 Impact factor: 12.969
Authors: G M Fuhrman; S D Leach; C A Staley; J C Cusack; C Charnsangavej; K R Cleary; A K El-Naggar; C J Fenoglio; J E Lee; D B Evans Journal: Ann Surg Date: 1996-02 Impact factor: 12.969